Literature DB >> 26497992

Histologic muscular history in steroid-treated and untreated patients with Duchenne dystrophy.

Lorenzo Peverelli1, Silvia Testolin1, Luisa Villa1, Adele D'Amico1, Stefania Petrini1, Chiara Favero1, Francesca Magri1, Lucia Morandi1, Marina Mora1, Tiziana Mongini1, Enrico Bertini1, Monica Sciacco1, Giacomo P Comi1, Maurizio Moggio2.   

Abstract

OBJECTIVE: Duchenne muscular dystrophy (DMD) is a lethal disease. The outcome measures used in numerous therapeutic trials include skeletal muscle biopsy. We studied the natural history of DMD from the standpoint of muscle histology with the aim of providing a reproducible tool for use in evaluating and comparing any histologic changes occurring in patients with DMD undergoing treatment and hence be able to determine how therapy modulates the histologic evolution of the disease.
METHODS: Three independent operators analyzed 56 muscle biopsies from 40 patients not treated with steroids, aged 1 to 10 years and 16 individuals treated with steroids, aged 7 to 10 years. We analyzed morphologic measures, normalized every measure for the average number of fibers observed for each year of age, and calculated intraclass correlation coefficients.
RESULTS: The average proportion of connective tissue in patients not treated with steroids was 16.98% from ages 1 to 6 years and 30% from ages 7 to 10 years (p < 0.0001). The average proportion in patients treated with steroids was 24.90%. Muscle fiber area mirrored that of connective tissue in both groups.
CONCLUSIONS: Having provided a reproducible tool for evaluation and comparison of histologic changes occurring in patients undergoing clinical trials, it was observed that at ages 6 to 7 years, fibrotic tissue rapidly peaks to 29.85%; this is a crucial moment when muscle tissue loses its self-regeneration ability, veering toward fibrotic degeneration. These data should be considered when deciding the most suitable time to begin therapy.
© 2015 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26497992      PMCID: PMC4662699          DOI: 10.1212/WNL.0000000000002147

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  35 in total

1.  Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands.

Authors:  K Bushby; F Muntoni; A Urtizberea; R Hughes; R Griggs
Journal:  Neuromuscul Disord       Date:  2004-09       Impact factor: 4.296

2.  Histopathological changes in Duchenne muscular dystrophy.

Authors:  C D Bell; P E Conen
Journal:  J Neurol Sci       Date:  1968 Nov-Dec       Impact factor: 3.181

Review 3.  Epigenetic control of skeletal muscle regeneration: Integrating genetic determinants and environmental changes.

Authors:  Lorenzo Giordani; Pier Lorenzo Puri
Journal:  FEBS J       Date:  2013-07-15       Impact factor: 5.542

4.  A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy.

Authors:  Jerry R Mendell; Zarife Sahenk; Vinod Malik; Ana M Gomez; Kevin M Flanigan; Linda P Lowes; Lindsay N Alfano; Katherine Berry; Eric Meadows; Sarah Lewis; Lyndsey Braun; Kim Shontz; Maria Rouhana; Kelly Reed Clark; Xiomara Q Rosales; Samiah Al-Zaidy; Alessandra Govoni; Louise R Rodino-Klapac; Mark J Hogan; Brian K Kaspar
Journal:  Mol Ther       Date:  2014-10-17       Impact factor: 11.454

Review 5.  Epigenetic regulation of skeletal muscle development and differentiation.

Authors:  Narendra Bharathy; Belinda Mei Tze Ling; Reshma Taneja
Journal:  Subcell Biochem       Date:  2013

6.  Fibroadipogenic progenitors mediate the ability of HDAC inhibitors to promote regeneration in dystrophic muscles of young, but not old Mdx mice.

Authors:  Chiara Mozzetta; Silvia Consalvi; Valentina Saccone; Matthew Tierney; Adamo Diamantini; Kathryn J Mitchell; Giovanna Marazzi; Giovanna Borsellino; Luca Battistini; David Sassoon; Alessandra Sacco; Pier Lorenzo Puri
Journal:  EMBO Mol Med       Date:  2013-03-18       Impact factor: 12.137

Review 7.  Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy.

Authors:  Eric P Hoffman; Erica Reeves; Jesse Damsker; Kanneboyina Nagaraju; John M McCall; Edward M Connor; Kate Bushby
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-11       Impact factor: 1.784

8.  Magnetic resonance imaging in Duchenne muscular dystrophy: longitudinal assessment of natural history over 18 months.

Authors:  Kieren G Hollingsworth; Penny Garrood; Michelle Eagle; Kate Bushby; Volker Straub
Journal:  Muscle Nerve       Date:  2013-08-30       Impact factor: 3.217

9.  Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy.

Authors:  Richard S Finkel; Kevin M Flanigan; Brenda Wong; Carsten Bönnemann; Jacinda Sampson; H Lee Sweeney; Allen Reha; Valerie J Northcutt; Gary Elfring; Jay Barth; Stuart W Peltz
Journal:  PLoS One       Date:  2013-12-11       Impact factor: 3.240

10.  The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study.

Authors:  Craig M McDonald; Erik K Henricson; R Ted Abresch; Julaine M Florence; Michelle Eagle; Eduard Gappmaier; Allan M Glanzman; Robert Spiegel; Jay Barth; Gary Elfring; Allen Reha; Stuart Peltz
Journal:  Muscle Nerve       Date:  2013-06-26       Impact factor: 3.217

View more
  18 in total

1.  Intermittent glucocorticoid steroid dosing enhances muscle repair without eliciting muscle atrophy.

Authors:  Mattia Quattrocelli; David Y Barefield; James L Warner; Andy H Vo; Michele Hadhazy; Judy U Earley; Alexis R Demonbreun; Elizabeth M McNally
Journal:  J Clin Invest       Date:  2017-05-08       Impact factor: 14.808

2.  Imaging respiratory muscle quality and function in Duchenne muscular dystrophy.

Authors:  Alison M Barnard; Donovan J Lott; Abhinandan Batra; William T Triplett; Sean C Forbes; Samuel L Riehl; Rebecca J Willcocks; Barbara K Smith; Krista Vandenborne; Glenn A Walter
Journal:  J Neurol       Date:  2019-07-26       Impact factor: 4.849

3.  Validation of ultrasonography for non-invasive assessment of diaphragm function in muscular dystrophy.

Authors:  Nicholas P Whitehead; Kenneth L Bible; Min Jeong Kim; Guy L Odom; Marvin E Adams; Stanley C Froehner
Journal:  J Physiol       Date:  2016-10-13       Impact factor: 5.182

4.  MR biomarkers predict clinical function in Duchenne muscular dystrophy.

Authors:  Alison M Barnard; Rebecca J Willcocks; William T Triplett; Sean C Forbes; Michael J Daniels; Saptarshi Chakraborty; Donovan J Lott; Claudia R Senesac; Erika L Finanger; Ann T Harrington; Gihan Tennekoon; Harneet Arora; Dah-Jyuu Wang; H Lee Sweeney; William D Rooney; Glenn A Walter; Krista Vandenborne
Journal:  Neurology       Date:  2020-02-05       Impact factor: 9.910

5.  One-year follow up of three Italian patients with Duchenne muscular dystrophy treated with ataluren: is earlier better?

Authors:  Lucia Ruggiero; Rosa Iodice; Marcello Esposito; Raffaele Dubbioso; Stefano Tozza; Floriana Vitale; Lucio Santoro; Fiore Manganelli
Journal:  Ther Adv Neurol Disord       Date:  2018-11-03       Impact factor: 6.570

6.  Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy.

Authors:  Navid Khan; Helen Eliopoulos; Lixin Han; T Bernard Kinane; Linda P Lowes; Jerry R Mendell; Heather Gordish-Dressman; Erik K Henricson; Craig M McDonald
Journal:  J Neuromuscul Dis       Date:  2019

7.  Simvastatin offers new prospects for the treatment of Duchenne muscular dystrophy.

Authors:  Nicholas P Whitehead; Min Jeong Kim; Kenneth L Bible; Marvin E Adams; Stanley C Froehner
Journal:  Rare Dis       Date:  2016-04-12

8.  Pharmacological inhibition of REV-ERB stimulates differentiation, inhibits turnover and reduces fibrosis in dystrophic muscle.

Authors:  Ryan D Welch; Cyrielle Billon; Aurore-Cecile Valfort; Thomas P Burris; Colin A Flaveny
Journal:  Sci Rep       Date:  2017-12-07       Impact factor: 4.996

9.  Hippo signaling pathway is altered in Duchenne muscular dystrophy.

Authors:  Gian Luca Vita; Francesca Polito; Rosaria Oteri; Roberto Arrigo; Anna Maria Ciranni; Olimpia Musumeci; Sonia Messina; Carmelo Rodolico; Rosa Maria Di Giorgio; Giuseppe Vita; M'Hammed Aguennouz
Journal:  PLoS One       Date:  2018-10-10       Impact factor: 3.240

10.  Magnetic Resonance Imaging Studies in Duchenne Muscular Dystrophy: Linking Findings to the Physical Therapy Clinic.

Authors:  Claudia R Senesac; Alison M Barnard; Donovan J Lott; Kavya S Nair; Ann T Harrington; Rebecca J Willcocks; Kirsten L Zilke; William D Rooney; Glenn A Walter; Krista Vandenborne
Journal:  Phys Ther       Date:  2020-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.